Companies / ADO

ANTEOTECH LTD

ASX:ADOPharmaceuticals, Biotechnology & Life Sciences
3.26B shares on issueASX (delayed) · as of 28 July 2026$0.022price · delayed$65.2Mmarket cap · indicative
C
Dilution grade

Share count grew 32% in 24 months; 3 cash raises in 24 months; runway 4–8 quarters

Cash runway6.5 quarters of funding
Share-count growth (24m)32.1%
Raise cadence (24m)3 cash raises
Options & rights overhang12.5% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

ANTEOTECH LTD's ordinary share count rose 32.1% between May 2024 and June 2026, to 3.26B shares. The company raised capital three times in that period for total proceeds of A$8.9M, most recently a A$3.8M placement in January 2026. Options and rights on issue could convert into 407M new shares, equal to 12.5% of the current share count, none of which are in the money at the current share price, with the nearest expiry in September 2026. At the June 2026 quarter the company reported A$10.8M in available cash, equivalent to 6.5 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
12.5%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
6.5 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 3.26B per ASX (delayed) (28 July 2026).
2.79B2.96B3.13BDec 24Sept 25July 26Cash raise · 21 Jan 2026

Cash runway

6.5 qtrs
More than four quarters of funding at the recent spend rate.
$10.8M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
17 July 20263G · unquotedORDINARY FULLY PAID3.26BAppendix 3G
3 June 20262A · quoted issueADO : ORDINARY FULLY PAID3.26BAppendix 2A
1 June 20262A · quoted issueADO : ORDINARY FULLY PAID3.09BAppendix 2A
11 May 20263H · cancellationADO : ORDINARY FULLY PAID2.97BAppendix 3H
9 Feb 20263H · cancellationADO : ORDINARY FULLY PAID2.97BAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

3 cash raises in the last 24 months · 1 in the last 12 months

$3.8M
Placement
21 Jan 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

12.5%
Total overhang · of current shares
0.0%
In the money · at current price
407.1M
Potential new shares
Sept 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
1 June 2026Geoff CummingOther—600k—3Y notice
1 June 2026Geoff CummingBuy585k—$20k3Y notice
1 June 2026Geoff CummingSell3.0M—$108k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

19 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
17 July 2026Notification regarding unquoted securities - ADO
16 July 2026Appointment of CFO and Company Secretary
30 June 2026ADO Completes CLIA Program- Advances Commercial Relationship
29 June 2026$PNew Product- Anteo C - launched and Shipped for Scale Trials
11 June 2026Investor Presentation Gold Coast Investment Showcase
4 June 2026Cleansing Notice
3 June 2026Change of Director's Interest Notice
3 June 2026Application for quotation of securities - ADO
1 June 2026Cleansing Notice
1 June 2026Application for quotation of securities - ADO
29 May 2026Proposed issue of securities - ADO
29 May 2026$PUnderwriting of Listed Options
27 May 2026ADO Expands into Japan with Life Sciences Distributor
25 May 2026Next Gen. Battery Separator Technology Term Sheet Signed
20 May 2026$PULTRANODE 95 VALIDATED IN CELL FORMAT SUITED FOR DRONE USE
11 May 2026Notification of cessation of securities - ADO
5 May 2026Notification of Upcoming Expiry of Listed ADOO Options
21 Apr 2026Investor Update Presentation
20 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.